Codexis logo
Codexis CDXS
$ 1.37 1.45%
report update icon

Quarterly report 2026-Q2
added 08-11-2026

Codexis Income Statement 2025-2008 | CDXS

Brief overview of profit and loss at Codexis

The comparison covers a five-year financial horizon. Revenue reported by Codexis was 69.1 million dollars at the beginning of the period and 70.4 million dollars at the end. The total change was +1.9%, with a CAGR of approximately 0.4%. The scale of the core business was largely unchanged.

Gross profit was $55.3 million at the start and $61 million at the end of the period (+10.4%). Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. At the margin level, the figure shifted from 80.1% to 86.7%. Improving gross profitability strengthens the quality of revenue growth.

EBITDA changed from −22 million dollars to −36.5 million dollars (−66.1%). EBITDA underperformed the top-line trend. Comparing the endpoints gives EBITDA margins of −31.8% and −51.8%. Cost pressure reduced operating profitability.

The net financial result changed from −24 million dollars to −44 million dollars. Larger losses indicate rising pressure on the business.

Market value was $1.3 billion at the start and $111 million at the end. Market expectations deteriorated over the period.

Conclusion

The indicators point to a weaker financial profile. The constructive conclusion rests on a stronger gross margin. The most visible risks are a narrow EBITDA buffer, a weaker final result and a softer top-line trend. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Codexis

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

111 M 291 M 247 M 299 M 2.02 B 1.3 B 906 M 924 M 414 M 191 M 160 M 146 M 70.7 M 83.1 M 208 M 266 M - -

Shares

87.1 M 73.4 M 68.1 M 65.3 M 64.6 M 59.4 M 56.5 M 52.2 M 46.2 M 40.6 M 39.4 M 38.2 M 38.2 M 36.8 M 35.7 M 24.6 M - -

Historical Prices

1.27 3.97 3.62 4.57 31.3 21.8 16 16.7 8.35 4.6 4.23 2.52 1.4 2.21 5.3 10.8 - -

Net Income

-44 M -65.3 M -76.2 M -33.6 M -21.3 M -24 M -11.9 M -10.9 M -23 M -8.56 M -7.58 M -19.1 M -41.3 M -30.9 M -16.6 M -8.54 M -20.3 M -

Revenue

70.4 M 59.3 M 70.1 M 139 M 105 M 69.1 M 68.5 M 60.6 M 50 M 48.8 M 41.8 M 35.3 M 31.9 M 88.3 M 124 M 107 M 82.9 M -

Cost of Revenue

9.34 M 16.3 M 12.8 M 38 M 22.2 M 13.7 M 15.6 M 12.6 M 14.3 M 9.75 M - - - - - - - -

Gross Profit

- - - - - - 52.8 M 48 M 35.7 M 39.1 M 35.2 M 25.6 M 17.4 M 57.7 M 82.1 M - - -

Operating Income

-41.7 M -58.5 M -68.1 M -34.9 M -22.7 M -23.9 M -12.5 M -11.3 M -23 M -8.56 M -7.77 M -19.1 M -41.1 M -30.5 M -15.9 M -7.12 M -18.4 M -

Interest Expense

-4.81 M -10.4 M -12.3 M 124 K 1.15 M -156 K -656 K -291 K -92 K -94 K - - 13 K - - 529 K - -

EBITDA

-36.5 M -53.6 M -62.6 M -29.5 M -19.6 M -22 M -7.99 M -10.1 M -21.9 M -4.02 M -2.36 M -12.4 M -30.8 M -18.1 M -4.44 M -6.06 M -17.4 M -

Operating Expenses

- - - - - - 31.5 M 29.3 M 29 M 25.4 M 22.3 M 21.9 M 26.9 M 31.4 M 98 M 114 M 101 M -

General and Administrative Expenses

47.1 M 55.1 M 53.2 M 52.2 M 49.3 M 35 M 31.5 M 29.3 M 29 M 25.4 M 22.3 M 21.9 M 26.9 M 31.4 M 36.9 M 33.8 M 29.9 M -

All numbers in USD currency

Quarterly Income Statement Codexis

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

85.4 M 90.8 M - 90.3 M 85.4 M 82.4 M 81.8 M 72 M 70.4 M 69.9 M 69.9 M 69.5 M 67.6 M 65.9 M 65.8 M 65.4 M 65.3 M 65.1 M 65.1 M 64.6 M 64.4 M 64.3 M 64.3 M 59.1 M 59 M 58.9 M 58.9 M 58.3 M 55 M 54.2 M 54.1 M 53.6 M 52.8 M 48.4 M 48.4 M 48.1 M 47.2 M 41.2 M 41.3 M 40.9 M 40.5 M 40.1 M 40.3 M 39.8 M 39.3 M 38.8 M 39.6 M 38.4 M 38 M 38.5 M 38.3 M 38.1 M 38.1 M 37.8 M 37.6 M 37.1 M 36.3 M 36.1 M 36 M 35.9 M 35.7 M 35.1 M

Net Income

-13.3 M -8.7 M - -19.6 M -13.3 M -20.7 M - -20.6 M -22.8 M -11.5 M - -34.9 M -11.5 M -22.6 M - -9.99 M -2.64 M -8.36 M - 2.24 M -4.26 M -9.07 M - -6.09 M -6.34 M -7.65 M - 343 K -6.51 M -5.14 M - -1.99 M -3.74 M -4.69 M - -10.2 M -6.28 M -7.46 M - 1.44 M 2.24 M -6.97 M - 5.39 M -5.36 M -5.56 M - -4.56 M -8.48 M -6.38 M -9.81 M -9.26 M -12.6 M -9.62 M -15.5 M -2.31 M -5.52 M -7.49 M -5.3 M -2.74 M -5.04 M -3.47 M

Revenue

15.3 M 15.2 M - 8.6 M 15.3 M 7.54 M - 12.8 M 7.98 M 17.1 M - 9.28 M 21.3 M 13 M - 34.5 M 38.4 M 35.3 M - 36.8 M 25.5 M 18 M - 18.4 M 15 M 14.7 M - 21.9 M 12.3 M 15.6 M - 16.9 M 13.5 M 14 M - 9.98 M 10.3 M 7.97 M - 14.9 M 16 M 8 M - 38.9 M 6.02 M 6.8 M - 7.47 M 6.57 M 7.07 M 9.52 M 3.94 M 6.97 M 11.5 M 7.91 M 26.3 M 22.9 M 31.1 M 33.5 M 33.3 M 26.1 M 31 M

Cost of Revenue

2.1 M 2.06 M - 2.46 M 2.1 M 2.73 M - 4.32 M 3.46 M 4.86 M - 2.25 M 3.18 M 4.52 M - 9.79 M 11.3 M 8.52 M - 6.87 M 4.32 M 4.22 M - 3.64 M 1.7 M 2.54 M - 5.07 M 2.77 M 4.39 M - 3.79 M 2.61 M 3.82 M - 3.98 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-12.9 M -8.04 M - -18.9 M -12.9 M -20.5 M - -16.6 M -22.7 M -11.9 M - -32.1 M -12.6 M -23.7 M - -10.6 M -2.61 M -8.39 M - 1.33 M -4.49 M -9.16 M - -6.06 M -6.11 M -7.83 M - 259 K -6.62 M -5.24 M - -2.11 M -3.84 M -4.71 M - -10 M -6.34 M -7.48 M - 1.42 M 2.25 M -6.98 M - 5.69 M -5.7 M -5.53 M - -4.26 M -8.91 M -6.4 M - -9.21 M -12.4 M -9.63 M - -2.16 M -5.36 M -7.25 M - -2.33 M -5.29 M -3.38 M

Interest Expense

-984 K -1.29 M - -1.29 M -984 K -942 K - -4.92 M -985 K -516 K - -3.9 M -9 K -25 K - 216 K -63 K -3 K - 983 K 23 K -88 K - -50 K 13 K -86 K - -403 K -88 K -125 K - -80 K -82 K -60 K - -68 K -34 K 22 K - 7 K -49 K 3 K - -26 K -96 K -25 K - - - - - - - - - - - - - - - -

EBITDA

-11.6 M -6.76 M - -17.6 M -11.6 M -19.3 M - -15.4 M -21.5 M -10.6 M - -30.7 M -11.1 M -22.2 M - -9.23 M -1.27 M -7.17 M - 2.1 M -3.77 M -8.5 M - -5.56 M -5.64 M -7.39 M - 1.38 M -5.93 M -4.92 M - -1.29 M -3.34 M -4.47 M - -9.24 M -5.78 M -7.15 M - 2.78 M 3.17 M -6.52 M - 7.26 M -4.62 M -4.97 M - -1.58 M -6.83 M -5.38 M - -3.91 M -8.91 M -7.83 M - 4.67 M -815 K -5.05 M - 454 K -3.43 M -2.44 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - 21.6 M 18.9 M 20.8 M - 19.1 M 17.4 M 18.7 M - 20 M 16.7 M 15.4 M - 13.5 M 13.8 M 15 M - 11.7 M 11.7 M 12.3 M - 11.7 M 15.5 M 13.5 M 19.4 M 13.2 M 19.4 M 21.1 M 23.7 M 28.5 M 28.3 M 38.4 M 38.4 M 35.6 M 31.3 M 34.4 M

General and Administrative Expenses

12.3 M 9.78 M - 11.2 M 12.3 M 12.4 M - 13.6 M 15.7 M 12.9 M - 12.3 M 13.4 M 15.4 M - 13.5 M 10.7 M 15.7 M - 13.4 M 12.8 M 11.4 M - 8.8 M 8.52 M 8.99 M - 7.87 M 7.9 M 8.42 M - 7.34 M 7.4 M 7.75 M - 7.99 M 6.55 M 6.61 M - 5.23 M 6.42 M 6.8 M - 5.42 M 5.3 M 5.58 M - 5.16 M 5.62 M 6.11 M 5.78 M 5.83 M 7.17 M 8.12 M 7.29 M 7.91 M 800 K 753 K 9.78 M 8.87 M 9.28 M 9.01 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Codexis (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AnaptysBio AnaptysBio
ANAB
$ 51.7 1.83 % $ 1.5 B usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.73 3.61 % $ 258 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.89 0.53 % $ 107 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Rezolute Rezolute
RZLT
$ 3.94 1.87 % $ 299 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.52 1.17 % $ 6.21 B israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 61.35 0.06 % $ 11.8 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 9.64 0.46 % $ 449 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 99.26 0.81 % $ 24 B germanyGermany
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 3.63 3.93 % $ 795 M britainBritain
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.17 0.46 % $ 3.57 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.24 0.35 % $ 1.27 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.03 0.3 % $ 251 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.61 0.38 % $ 497 M usaUSA
AbbVie AbbVie
ABBV
$ 265.12 0.09 % $ 469 B usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.17 1.48 % $ 137 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.65 2.76 % $ 3.78 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.43 2.65 % $ 288 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.48 1.16 % $ 2.09 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.12 1.98 % $ 50.3 M israelIsrael
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 2.08 0.48 % $ 5.43 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.15 1.67 % $ 13 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.64 0.85 % $ 717 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 118.51 4.93 % $ 12.3 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.45 0.19 % $ 99.2 M usaUSA
Curis Curis
CRIS
$ 0.88 0.85 % $ 11.6 M usaUSA
CorMedix CorMedix
CRMD
$ 7.77 1.04 % $ 560 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.7 0.23 % $ 5.01 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 11.8 8.21 % $ 932 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.95 0.38 % $ 68.5 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.88 0.62 % $ 935 M canadaCanada
Cue Biopharma Cue Biopharma
CUE
$ 32.85 3.6 % $ 3.11 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.72 2.38 % $ 13.8 M usaUSA